Valuation: ProPhase Labs, Inc.

Market Cap 435K 373K 348K 319K 600K 41.53M 610K 4.11M 1.61M 20.83M 1.63M 1.6M 68.87M P/E 2024
-0.29x
P/E 2025 -0.26x
Enterprise Value 8.96M 7.69M 7.18M 6.59M 12.39M 857M 12.59M 84.71M 33.17M 430M 33.65M 32.92M 1.42B EV / Sales 2024
6.2x
EV / Sales 2025 2.44x
Free-Float
91.93%
Yield 2024 *
-
Yield 2025 -

Last Transcript: ProPhase Labs, Inc.

1 day-3.15%
1 week-32.89%
Current month-28.17%
1 month-57.11%
3 months-70.65%
6 months-81.48%
Current year-93.30%
1 week 0.03
Extreme 0.028
0.05
1 month 0.03
Extreme 0.028
0.07
Current year 0.03
Extreme 0.028
0.47
1 year 0.03
Extreme 0.028
6.66
3 years 0.03
Extreme 0.028
74.8
5 years 0.03
Extreme 0.028
152.5
10 years 0.03
Extreme 0.028
160.4
Manager TitleAgeSince
Chief Executive Officer 67 19/06/2009
Director of Finance/CFO 66 06/08/2025
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 67 19/06/2009
Director/Board Member 70 01/06/2009
Director/Board Member 56 20/06/2025
Date Insider Type Main position Quantity % Market Cap.
09/09/25 Free

Chief Executive Officer

500,000 1.2036%
17/02/25 Free

Chief Operating Officer

500,000 1.6737%
14/02/25 Free

Director

100,000 0.3347%
Change 5-day change 1-year change 3-year change Capi.($)
-3.15%-32.89%-99.04%-99.94% 435K
+2.59%+1.19%+99.68%+482.17% 44.93B
+1.83%+0.96%+18.42%+51.45% 26.13B
+2.35%+4.25%-17.33%-27.66% 8.07B
+2.42%-1.72%+11.34%+147.64% 5.81B
-0.75%-3.22%+10.08%+68.35% 3.32B
+3.11%-3.99%-34.43%+1,604.85% 2.28B
+2.52%-0.61%+158.64%+15.91% 2.04B
-3.39%-11.13%-9.92%-55.68% 1.99B
+0.27%+0.22%+31.02%+19.46% 1.88B
Average +0.79%-6.36%+16.84%+220.66% 9.64B
Weighted average by Cap. +2.11%-0.77%+53.96%+284.95%

Financials

2024 2025
Net sales 6.77M 5.81M 5.42M 4.98M 9.36M 647M 9.51M 63.99M 25.06M 325M 25.42M 24.87M 1.07B 4.34M 3.73M 3.48M 3.19M 6M 415M 6.1M 41.07M 16.08M 208M 16.31M 15.96M 689M
Net income -53.36M -45.78M -42.74M -39.22M -73.75M -5.1B -74.96M -504M -198M -2.56B -200M -196M -8.46B -14.74M -12.65M -11.81M -10.83M -20.37M -1.41B -20.71M -139M -54.56M -707M -55.36M -54.15M -2.34B
Net Debt 23.9M 20.5M 19.14M 17.56M 33.02M 2.28B 33.57M 226M 88.44M 1.15B 89.72M 87.77M 3.79B 8.53M 7.32M 6.83M 6.27M 11.79M 815M 11.98M 80.6M 31.56M 409M 32.02M 31.32M 1.35B
Logo ProPhase Labs, Inc.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Employees
19
Date Price Change Volume
19/08/26 $0.0300 -3.15% 172,650
18/08/26 $0.0310 +3.33% 257,204
17/08/26 $0.0300 -25.00% 2,209,512
14/08/26 $0.0400 -0.25% 24,007
13/08/26 $0.0401 -10.29% 308,135

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRPH Stock